Drug Profile
Research programme: plasma-derived biopharmaceuticals - Liminal BioSciences
Alternative Names: Alpha-1 antitrypsin deficiency therapy - Liminal BioSciences; C1 INH - Liminal BioSciences; Haemophilia therapeutics - Liminal BioSciences; Plasma-derived orphan drug products - Liminal BioSciencesLatest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator ProMetic Life Sciences
- Developer Liminal BioSciences
- Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Alpha 1-antitrypsin replacements; Blood coagulation stimulants; Complement C1 inhibitors; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alpha 1-antitrypsin deficiency; Haemophilia; Hereditary angioedema
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Hereditary-angioedema in Canada
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
- 28 Jan 2019 No recent reports of development identified for research development in Haemophilia in Canada